A Phase I/II Trial of Sapanisertib in Advanced Anaplastic and Radioiodine Refractory Differentiated Thyroid Carcinoma - Quiz - MDSpire

A Phase I/II Trial of Sapanisertib in Advanced Anaplastic and Radioiodine Refractory Differentiated Thyroid Carcinoma

  • By

  • Kartik Sehgal

  • Anthony Serritella

  • Mofei Liu

  • Anne ONeill

  • Chaitali Nangia

  • Theodora Pappa

  • Michael J Demeure

  • Francis P Worden

  • Robert I Haddad

  • Jochen Lorch

  • June 29, 2024

  • 0 min

Share

Original Source(s)

A Phase I/II Trial of Sapanisertib in Advanced Anaplastic and Radioiodine Refractory Differentiated Thyroid Carcinoma

  • by Kartik Sehgal, Anthony Serritella, Mofei Liu, Anne ONeill, Chaitali Nangia, Theodora Pappa, Michael J Demeure, Francis P Worden, Robert I Haddad, Jochen Lorch

  • June 29, 2024

Related Content

The Loan Cap That Could Shrink the Doctor Pipeline

New federal limits on medical school borrowing may quietly reshape who becomes a physician—and where they practice.

A novel marker for predicting malignancy in patients with thyroid nodules diagnosed as AUS on initial cytology: thyroid hormone sensitivity

JAMA Otolaryngology–Head & Neck Surgery —The Year in Review, 2025